The Why Behind Pigmentary Disorders Exchange Symposium
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium interviewed Dr. Pearl E. Grimes, symposium chair and clinical professor of dermatology at the University of California, Los Angeles. Hear the “why” behind the Pigmentary Disorders Exchange Symposium from its founding chair. Learn what Dr. Grimes believes is a common myth about pigmentary disorders. Plus hear what m …
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium interviewed Dr. Pearl E. Grimes, symposium chair and clinical professor of dermatology at the University of California, Los Angeles. Hear the “why” behind the Pigmentary Disorders Exchange Symposium from its founding chair. Learn what Dr. Grimes believes is a common myth about pigmentary disorders. Plus hear what m … Continue reading "The Why Behind Pigmentary Disorders Exchange Symposium"
Mainstream medical dermatology is changing, and it’s about time, says Dr. R. Rox Anderson, professor at Harvard Medical School and director of the Wellman Center for Photomedicine at Massachusetts General Hospital. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Anderson about the future of product innovation. Hear what Dr. Anderson … 
Ciclopirox is the only hydroxypyridone antifungal agent with a unique mechanism of action differentiating it from other antimycotic agents. Unlike the azole-antifungals which block the sterol synthesis in the fungal cell membrane, ciclopirox functions by chelating cations resulting in the degradation of fungal cells, as well as proposed anti-inflammatory properties. It is available in a variety of … 
ABSTRACT
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, and extranodal involvement is seen in approximately 40% of cases. However, cases involving the skin and muscle are rare, and skin manifestations most commonly present as plaques, papules, small nodules, or ulcers. In this report, JDD authors Lauren E. Merz MD MSc, Christopher B. Hergott MD PhD, and Reb … 
Be excited about the new medications approved for use in pediatric patients, says Dr. A. Yasmine Kirkorian, chief of dermatology at Children’s National Hospital. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Kirkorian about the use of JAK inhibitors in children. Should dermatology clinicians prescribe JAK inhibitors in this patient … 